Europe Approved Sutent for Rare Pancreatic Cancer

Print pagePDF pageEmail page

The European Commission has recently approved Sutent (sunitinib) as a medicine for treating patients with pancreatic neuroendocrine tumors (NET).  

The drug is now indicated to treat unresectable metastatic, well-differentiated pancreatic NET in adults with disease progression. 

The approval was based on a Phase III study which was reported in January.  The study showed that patients with pancreatic NET and treated with Sutent had progression-free survival of 1.4 months, compared with 5.5 months for placebo. 

Please visit healthreason.com for more health related articles.

Print Friendly
Be Sociable, Share!
This entry was posted in Cancer, Pancreatic Cancer and tagged , , , , , . Bookmark the permalink.
0 comments